SKNV, a Florida-based company involved in dermatologic innovation and custom prescription medications, announced on Wednesday the launch of Kefunova Cream (Fluorouracil 5% / Calcipotriene 0.005%).

The new prescription-only topical therapy was developed in response to the needs of dermatology providers treating actinic keratosis (AK) and superficial basal cell carcinoma (sBCC).

According to SKNV, Kefunova combines two time-tested active ingredients -- Fluorouracil, a topical chemotherapy agent, and Calcipotriene, a vitamin D analogue -- to support a synergistic treatment approach. Together, they promote lesion clearance through enhanced immune activation and cell turnover.

Kefunova is manufactured at SKNV's FDA-Registered 503B Outsourcing Facility, which operates under strict CGMP standards. The cream arrives ready-to-use and is available for both in-office dispensing and e-prescribing through EMR systems.

"Kefunova is exactly what dermatology providers have been asking for -- a trusted, high-quality option to target actinic keratosis and superficial basal cell carcinoma," said Spencer Malkin, CEO of SKNV. "It answers a clear need in the clinical community for medications that integrate seamlessly into treatment plans. With a well-established mechanism and a formulation built for reliability and convenience, Kefunova is designed to support both dispensing in-office as well as prescribing direct-to-patient."